h
Let’s Work Together
[email protected]

Meet Arrosa, the perfect theme to elevate your online presentation with.

Search here!
Eduardo Anitua_fondo

Eduardo Anitua

MD, DDS, PhD

Leiter des Instituts Eduardo Anitua, Institut für grundlagenorientierte und angewandte Forschung und klinisches Zentrum sowie Schulungszentrum in oraler Implantologie und regenerativer Therapie. Wissenschaftlicher Leiter am BTI (Biotechnology Institute).

Studium der Medizin und Chirurgie an der Universität Salamanca im Jahr 1979, Promotion in Medizin und Chirurgie.

Spezialist für Stomatologie an der Universität des Baskenlandes mit Weiterbildungen in den USA (Philadelphia, New York, Miami, San Francisco, Chicago) und Europa (Italien, Deutschland, Frankreich und natürlich Spanien).

Dozent an Konferenzen an verschiedenen spanischen und internationalen Universitäten sowie von postgradualen Weiterbildungen für Implantologie an den Universitäten Sevilla, Murcia, Barcelona und Madrid.

Redner an über 500 Kursen und Konferenzen zum Thema Implantologie, Prothetik, ästhetische Zahnmedizin und Geweberegeneration auf nationalen und internationalen Kongressen (Europa, USA, Südamerika, Asien).

Leiter des Fortbildungsprogramms in Implantologie und oraler Rehabilitation, das seit 22 Jahren in Spanien, Mexiko, Portugal, Italien und Deutschland durchgeführt wird.

Gastprofessur an den zahnmedizinischen Fakultäten der Universität Guatemala, der Interkontinentalen Universität Mexiko, der Päpstlichen Universität Javeriana in Kolumbien und an verschiedenen Universitäten in Argentinien, Uruguay, Portugal (Porto und Lissabon), Pennsylvania, Harvard, Boston und Tufts.

Leiter von Dental Dialogue.

Veröffentlichte artikel

Macrophages are innate immune cells that display remarkable phenotypic heterogeneity and functional plasticity. Due to their involvement in the pathogenesis of several human conditions, macrophages are considered to be an attractive therapeutic target. In line with this, platelet derivatives have been successfully applied in many medical fields and as active participants in innate immunity, cooperation between platelets and macrophages is essential. In this context, the aim of this review is to compile the current evidence regarding the effects of platelet derivatives on the phenotype and functions of macrophages to identify the advantages and shortcomings for feasible future clinical applications.

Chronic skin ulceration is a serious pathological condition for which the adjuvant use of platelet-rich plasma (PRP) has been indicated. However, evidence for the use of PRP in patients with chronic skin ulcers remains insufficient due to a large heterogeneity in experimental designs, PRP composition, and preparation protocols.

Dent J (Basel). 2024 Apr 24;12(5):122. The osteogenic differentiation process, by which bone marrow mesenchymal stem cells and osteoprogenitors transform into osteoblasts, is regulated by several growth factors, cytokines, and hormones. Plasma Rich in Growth Factors (PRGF) is a blood-derived preparation consisting of a plethora of bioactive molecules, also susceptible to containing epigenetic factors such as ncRNAs and EVs, that stimulates tissue regeneration. The aim of this study was to investigate the effect of the PRGF clot formulation on osteogenic differentiation. Firstly, osteoblast cells were isolated and characterised. The proliferation of bone cells cultured onto PRGF clots or treated with PRGF supernatant was determined.

  • Autor:
  • Eduardo Anitua
  • Troya M
  • Zalduendo M
  • Tierno R
  • Alkhraisat MH
  • Osinalde N
  • Fullaondo A
  • Zubiaga AM

Biomed Pharmacother. 2024 May:174:116599. The aim of this study was to produce and characterize triple-layered cell sheet constructs with varying cell compositions combined or not with the fibrin membrane scaffold obtained by the technology of Plasma Rich in Growth Factors (mPRGF).

  • Autor:
  • Eduardo Anitua
  • Lozano-Sanroma J
  • Barros A
  • Alcalde I
  • Alvarado-Villacorta R
  • Sánchez-Ávila RM
  • Queiruga-Piñeiro J
  • Cueto LF
  • Merayo-Lloves J

Diseases. 2024 Apr 11;12(4):76. Congenital aniridia is a rare bilateral ocular malformation characterized by the partial or complete absence of the iris and is frequently associated with various anomalies, including keratopathy, cataract, glaucoma, and foveal and optic nerve hypoplasia. Additionally, nearly 50% of individuals with congenital aniridia experience symptoms of ocular dryness. Traditional treatment encompasses artificial tears and autologous serum. This study aimed to assess the effectiveness and safety of using platelet rich in growth factors (PRGF) plasma in patients with congenital aniridia and ocular dryness symptoms.

Videos available on BTI Channel

In addition to this small sample, on BTI Channel you can increase your knowledge about oral implantology, regenerative medicine and sleep apnoea.

Eduardo Anitua
Extra kurze Implantate in der Einzelzahnversorgung
Eduardo Anitua
Erhaltung des Alveolarkamms in der ästhetischen Zone